Related Experiment Video
Updated: Jul 26, 2026

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
Published on: September 26, 2011
Steady state assumptions in DALYs: effect on estimates of HIV impact
1Department of International Health, School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
Objective:
The disability adjusted life year (DALY) and the healthy life year (HeaLY) are both composite indicators of disease burden in a population, which combine healthy life lost from mortality and morbidity. The two formulations deal with the onset and course of a disease differently. The purpose of this paper is to compare the DALY and HeaLY formulations as to differences in apparent impact when a disease is not in an epidemiological steady state and to explore the implications of the differing results.
Design:
HIV is used as a case study of a major disease that is entering its explosive growth phase in large areas of Asia. Data from the global burden of disease study of the World Bank and World Health Organisation for 1990 has been used to compare burden of disease measures in the two formulations.
Setting:
The data pertain to global and regional estimates of HIV impact.
Results:
The DALY attributes life lost from premature mortality to the year of death, while the HeaLY to the year of disease onset. This results in very large differences in estimates of healthy life lost based upon the DALY construct as compared with the HeaLY, for diseases such as HIV or those with a strong secular trend.
Conclusion:
The demonstration of the dramatic difference between the two indicators of disease burden reflects a limitation of the DALY. This information may directly influence decision making based on such methods and is critical to understand.
Related Concept Videos
Retrovirus Life Cycles
Steady State Concentration
Most drugs are administered in repeated doses at fixed intervals or through continuous intravenous...
Pharmacodynamic Models: Linear Concentration–Effect Model
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Assumptions of Survival Analysis

